ArticleBMC ophthalmology2025
Selective laser trabeculoplasty for the treatment of intraocular pressure elevation after viscocanalostomy with Ologen implant in the management of primary open-angle glaucoma: a retrospective cohort study.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined phacogoniosynechialysis with viscocanalostomy and Ologen implant for the management of primary angle-closure glaucoma: a retrospective cohort pilot study.BMC ophthalmology · 2026Article
- Short-term results of 360° selective laser trabeculoplasty in patients with failed deep sclerectomy.International journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSelective laser trabeculoplasty (SLT) is a non-invasive treatment option for glaucoma. It uses a Q-switched Nd: YAG laser. The aim of this study was to evaluate the efficacy of SLT as a treatment option for eyes with primary open-angle glaucoma (POAG) that have previously undergone viscocanalostomy with an Ologen implant, displaying uncontrolled intraocular pressure (IOP).
methodsThis retrospective cohort study included 26 eyes of 26 patients with POAG who had had SLT after viscocanalostomy or phacoviscocanalostomy with Ologen implant. These eyes showed a progression of glaucomatous damage, the IOP was above 21 mmHg, or with intolerable glaucoma medications. SLT was done using Tango Reflex multimodality YAG/SLT laser which is a Q-switched Nd: YAG laser producing a single 532 nm wavelength pulse with a 400 mm spot size and 3 ns pulse duration. The follow-up period was one year.
resultsOne year post-SLT, complete success was achieved in 19 cases (73.1%), qualified success in 4 cases (15.4%), and failure in 3 cases (11.5%). The mean decrease in IOP was 5.64 ± 4.05 mmHg, the mean reduction of antiglaucoma medications was 1.00 ± 0.85, and the mean percentage of reduction in IOP was 23.5 ± 16.4. There was a statistically significant decrease in IOP and antiglaucoma medications (p = < 0.01).
conclusionSLT is a simple and effective procedure that can be used as a treatment option for eyes with POAG after viscocanalostomy with Ologen implant to reach the target IOP and decrease the number of antiglaucoma medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.